Companies: 10,795·Total market cap: $144.5T
Biodesix, Inc.

Biodesix, Inc.

BDSXNASDAQHealthcare● Active
$15.41
+$0.46(+3.08%)
Market Cap$125441699
P/E Ratio
52W High$20.21
52W Low$5
Overview

Biodesix, Inc. (BDSX) PE Ratio — Current & Historical Data

Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.

bdsx · pe ratio · data through Dec 31, 2025

Core PE Ratio Metrics

Trailing 12 months · TTM

The price-to-earnings (P/E) ratio for Biodesix, Inc. (BDSX) measures how much investors pay for each dollar of the company's trailing earnings. BDSX's current PE ratio of N/A is calculated by dividing its stock price of $15.41 by its TTM earnings per share of -$3.31.

N/A
P/E Ratio (TTM)N/A — Company is not profitable (TTM)

Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31

Forward P/E
N/A
FY2027 est. EPS $-1.82
Based on 3 analysts
EPS (TTM)
-$3.31
TTM · diluted EPS
PEG Ratio
-0.13
Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Biodesix, Inc. SEC 10-K & 10-Q filings · US GAAPUpdated: 2026-06-09

PE Ratio History

2018 – 2025 · Annual
PE Ratio (TTM)
EPS (Annual)

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)

PE Ratio vs Peers

Medical - Diagnostics & Research · 6 peers · Annual PE
CompanyMarket CapPE (Annual)vs AvgEPS (TTM)
Biodesix, Inc.
Biodesix, Inc.You
BDSX
$125MN/A-$3.31
Aligos Therapeutics, Inc.
Aligos Therapeutics, Inc.
ALGS
$32MN/A-$2.45
INmune Bio, Inc.
INmune Bio, Inc.
INMB
$34MN/A-$1.73
Mersana Therapeutics, Inc.
Mersana Therapeutics, Inc.
MRSN
$145MN/A-$14.12
Inotiv, Inc.
Inotiv, Inc.
NOTV
$3MN/A-$2.11
OnKure Therapeutics, Inc.
OnKure Therapeutics, Inc.
OKUR
$63MN/A-$4.40
PDS Biotechnology Corporation
PDS Biotechnology Corporation
PDSB
$56MN/A-$0.74

* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio

Annual PE Ratio History

Showing 8 of 8 years
Fiscal Year EndPE RatioEPS (TTM)YoY ChangePE vs Max
2025-12-31Latest
FY2025
$-4.67
2024-12-31
FY2024
$-6.62
2023-12-31
FY2023
$-12.70
2022-12-31
FY2022
$-31.09
2021-12-31
FY2021
$-31.54
2020-12-31
FY2020
$-6.48
2019-12-31
FY2019
$-0.67
2018-12-31
FY2018
$-19.72

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API

About PE Ratio & Methodology

The price-to-earnings (P/E) ratio for Biodesix, Inc. (BDSX) measures how much investors pay for each dollar of the company's trailing earnings. BDSX's current PE ratio of N/A is calculated by dividing its stock price of $15.41 by its TTM earnings per share of -$3.31.

PE Ratio = Stock Price ÷ EPS (TTM)
= $15.41 ÷ -$3.31 = N/A
TTMTrailing Twelve Months — sum of the most recent 4 quarterly EPS figures
Forward PEStock price ÷ analyst consensus EPS estimate for the next fiscal year
PEGPE ÷ earnings growth rate — values below 1.0 suggest growth may justify the premium
Figures tie to SEC 10-K/10-Q and FMP ratio endpoints where noted.

Frequently asked questions

BDSX pe ratio · 6 questions

BDSX's current PE ratio is N/A as of 2026-06-09, based on a stock price of $15.41 and TTM EPS of -$3.31. Data sourced from Financial Modeling Prep via BDSX's SEC 10-K and 10-Q filings.

BDSX PE ratioWhat is BDSX PE ratioCurrent PE ratio of BDSXBDSX PE ratio today

Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Biodesix, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09